3billion
3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as … Read more
3billion (394800) - Net Assets
Latest net assets as of March 2025: ₩26.70 Billion KRW
Based on the latest financial reports, 3billion (394800) has net assets worth ₩26.70 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩32.58 Billion) and total liabilities (₩5.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩26.70 Billion |
| % of Total Assets | 81.93% |
| Annual Growth Rate | 14.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 75.74 |
3billion - Net Assets Trend (2021–2024)
This chart illustrates how 3billion's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 3billion (2021–2024)
The table below shows the annual net assets of 3billion from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩28.27 Billion | +139.86% |
| 2023-12-31 | ₩11.79 Billion | -27.75% |
| 2022-12-31 | ₩16.31 Billion | -12.82% |
| 2021-12-31 | ₩18.71 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 3billion's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1475500278000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩3.17 Billion | 11.21% |
| Other Components | ₩121.45 Billion | 429.61% |
| Total Equity | ₩28.27 Billion | 100.00% |
3billion Competitors by Market Cap
The table below lists competitors of 3billion ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Canoe EIT Income Fund
PINK:ENDTF
|
$98.99K |
|
COZX
BATS:COZX
|
$99.01K |
|
Invesco Pennsylvania Value Municipal Income Trust
NYSE:VPV
|
$99.01K |
|
Lake Superior Acquisition Corp. Class A Ordinary Shares
NASDAQ:LKSP
|
$99.07K |
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
$98.91K |
|
DP Cap Acquisition Corp I Warrants
NASDAQ:DPCSW
|
$98.89K |
|
ORVR3F
SA:ORVR3F
|
$98.87K |
|
DRAX GROUP - Dusseldorf Stock Exchang
DU:D9F2
|
$98.84K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 3billion's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,786,296,780 to 28,270,627,470, a change of 16,484,330,690 (139.9%).
- Net loss of 6,571,645,550 reduced equity.
- Share repurchases of 15,316,689,480 reduced equity.
- New share issuances of 15,316,689,480 increased equity.
- Other factors increased equity by 23,055,976,240.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-6.57 Billion | -23.25% |
| Share Repurchases | ₩15.32 Billion | -54.18% |
| Share Issuances | ₩15.32 Billion | +54.18% |
| Other Changes | ₩23.06 Billion | +81.55% |
| Total Change | ₩- | 139.86% |
Book Value vs Market Value Analysis
This analysis compares 3billion's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.49x to 17.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩595.11 | ₩15170.00 | x |
| 2022-12-31 | ₩518.79 | ₩15170.00 | x |
| 2023-12-31 | ₩374.83 | ₩15170.00 | x |
| 2024-12-31 | ₩892.27 | ₩15170.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 3billion utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -113.85%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.07x
- Recent ROE (-23.25%) is above the historical average (-100.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -315.85% | -10733.47% | 0.03x | 1.10x | ₩-60.98 Billion |
| 2022 | -19.28% | -379.60% | 0.03x | 1.70x | ₩-4.78 Billion |
| 2023 | -43.20% | -186.50% | 0.12x | 1.94x | ₩-6.27 Billion |
| 2024 | -23.25% | -113.85% | 0.19x | 1.07x | ₩-9.40 Billion |
Industry Comparison
This section compares 3billion's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 3billion (394800) | ₩26.70 Billion | -315.85% | 0.22x | $98.93K |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |